stockrow
Friday 6 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL Healthcare Biotechnology
- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.72
1.70
+8.49%
Follow REPL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(90.88%) | (107.88%) | (134.29%) | (115.80%) | |
| (67.19%) | (71.05%) | (82.28%) | (71.01%) | ||
ROIC |
(1,825.35%) | (8,036.55%) | (1,154.69%) | (928.27%) | |
Return on Tangible Assets |
(128.98%) | (134.24%) | (170.45%) | (93.72%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(3.07) | (3.07) | (2.90) | (2.34) | |
Free Cash Flow |
(283.27) | (284.57) | (280.54) | (245.69) | |
Capital Expenditures |
(5.35) | (4.22) | (1.49) | (0.14) | |
| Other line items | |||||
Cash ROIC |
(51.56%) | (52.67%) | (68.97%) | (38.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
— | — | — | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(40.90) | (36.11) | (29.92) | (24.59) | |
Operating CF/Net income |
0.88 | 0.89 | 0.94 | 0.91 | |
Depreciation/Fixed assets |
(0.05) | 0.06 | 0.18 | 0.28 | |
Capex/Depreciation |
7.04 | (5.37) | (0.71) | (0.05) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.01) | (3.02) | (2.88) | (2.33) | |
Capex per Share |
(0.06) | (0.05) | (0.02) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026